Immune Response against SARS-CoV-2
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 20959
Special Issue Editor
Special Issue Information
Dear Colleagues,
Human coronaviruses (HCoVs), which emerge periodically worldwide, pose a threat to human health as the severe acute respiratory syndrome coronavirus-2 (SARS's-CoV-2) disease called COVID-19. Despite much research around the world, the immune response induced by SARS-CoV-2 infection is a central issue that remains unclear. From the earliest days of the pandemic, it has been evident that patients respond differently to SARS-CoV-2 infection, varying from no symptoms to the need for hospitalization because of it. Finding the explanation for this variability was the main goal of COVID-19 research. How the immune system responds to viral infection - depending on age, sex, viral load, genetics, and other known and unknown variables - largely defines the course of the disease. Successful elimination of the virus from cured patients indicates the presence of adequate adaptive immune cells, as well as immune regulatory molecules and neutralizing antibodies. However, impairment of the adaptive immune response, along with hyperactivation of the innate immune system, can cause severe disease symptoms in COVID-19 patients. Several scientific studies demonstrate the occurrence of autoinflammatory/autoimmune phenomena in patients with COVID-19, such as antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barré syndrome, and Kawasaki disease, suggesting that the heterogeneity of virus-induced disorders results from molecular mimicry phenomena between the virus and human proteins. Furthermore, to date, while there is evidence of both B-cell and memory T-cell immune responses in individuals infected with SARS-CoV-2, as well as in vaccinated persons, clear correlates of protective immunity have yet to be defined.
Therefore, it is time to welcome contributions for this special issue of Vaccines, "Immune response against SARS-CoV-2." The goal is to provide comprehensive information on all aspects of research related to the immune response against SARS-CoV-2 .
This special issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the immune response in individuals infected or vaccinated against SARS-CoV-2. Both basic and applied research papers that aim to improve the understanding of the immune response against SARS-CoV-2, short- and long-term effects of host immune responses to SARS-CoV-2, improved diagnostic methods, vaccination-related immune response, and intervention strategies for the prevention and management of COVID-19-related autoimmune reactions are welcome.
We cordially invite you to contribute to this special issue to advance our knowledge of SARS-CoV-2 and to discover together the means to overcome the pandemic.
I look forward to receiving your contributions.
Dr. Angela Stufano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immune response
- adapative immunity
- vaccinations
- molecular mimicry
- T-cells immune response
- autoimmunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.